Invention Grant
US08236295B1 Composition comprising an adenoviral expression vector comprising a CD40L fusion protein for generating immune responses
有权
包含包含用于产生免疫应答的CD40L融合蛋白的腺病毒表达载体的组合物
- Patent Title: Composition comprising an adenoviral expression vector comprising a CD40L fusion protein for generating immune responses
- Patent Title (中): 包含包含用于产生免疫应答的CD40L融合蛋白的腺病毒表达载体的组合物
-
Application No.: US13364370Application Date: 2012-02-02
-
Publication No.: US08236295B1Publication Date: 2012-08-07
- Inventor: Albert B. Deisseroth , Lixin Zhang
- Applicant: Albert B. Deisseroth , Lixin Zhang
- Applicant Address: US VA Manassas
- Assignee: VAXum, LLC
- Current Assignee: VAXum, LLC
- Current Assignee Address: US VA Manassas
- Agent Jacob Frank; Glenn Snyder
- Main IPC: A61K48/00
- IPC: A61K48/00 ; C12N15/00
Abstract:
Provided are adenoviral vectors for generating an immune response to antigen. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal sequence upstream of a tumor antigen upstream of CD40 ligand, which is missing all or substantially all of the transmembrane domain rendering CD40L secretable. Also provided are methods of generating an immune response against cells expressing a tumor antigen by administering an effective amount of the invention vector. Further provided are methods of generating an immune response against cancer expressing a tumor antigen in an individual by administering an effective amount of the invention vector. Still further provided are methods of generating immunity to infection by human papilloma virus (HPV) by administering an effective amount of the invention vector which encodes the E6 or E7 protein of HPV. The immunity generated is long term.
Public/Granted literature
- US20120195924A1 ADENOVIRAL VECTOR VACCINE Public/Granted day:2012-08-02
Information query
